Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis

Tsu Chen Lin, Lie Yee Hung, Ying Chun Chen, Wei Cheng Lo, Chun Hung Lin, Ka Wai Tam, Mei Yi Wu

Research output: Contribution to journalArticle

Abstract

BACKGROUND/OBJECTIVE: Hyperuricemia has been proven to be an independent risk factor for chronic kidney disease (CKD). However, the role of hyperuricemia in the progression of CKD remains unclear. Thus, we performed a systematic review and meta-analysis to evaluate the efficacy and safety of febuxostat, a first line urate-lowering agent, in CKD patients with hyperuricemia. METHODS: We have systematically searched for randomized controlled trials assessing the efficacy and safety of febuxostat versus control in CKD patients with hyperuricemia through MEDLINE, PubMed, EMBASE, and Cochrane databases. All statistical analyses were conducted by using the statistical package Review Manager, version 5.3.5. Heterogeneity was assessed using the Cochrane Q and I tests and summary statistics were reported with 95% confidence interval. Two-tailed test was used for analysis and a P value of <.05 is considered statistically significant. RESULTS: Eleven eligible trials with 1317 participants were included in the meta-analysis. A significant reduction in serum uric acid was found in the febuxostat treated group. Also, a significant higher eGFR was found in the febuxostat treated group among CKD stage 3 and 4 patients. No significant difference of major complication or death was identified between treatment and control groups. CONCLUSIONS: The meta-analysis showed that other than its urate-lowering effect, febuxostat presented a reno-protective effect in CKD patients. More studies with larger sample sizes and higher quality are required to clarify the role of febuxostat use in the progression of CKD.

Original languageEnglish
Pages (from-to)e16311
JournalMedicine
Volume98
Issue number29
DOIs
Publication statusPublished - Jul 1 2019

Fingerprint

Chronic Renal Insufficiency
Meta-Analysis
Hyperuricemia
Kidney
Uric Acid
Safety
Febuxostat
PubMed
MEDLINE
Sample Size
Randomized Controlled Trials
Databases
Confidence Intervals
Control Groups
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effects of febuxostat on renal function in patients with chronic kidney disease : A systematic review and meta-analysis. / Lin, Tsu Chen; Hung, Lie Yee; Chen, Ying Chun; Lo, Wei Cheng; Lin, Chun Hung; Tam, Ka Wai; Wu, Mei Yi.

In: Medicine, Vol. 98, No. 29, 01.07.2019, p. e16311.

Research output: Contribution to journalArticle

@article{97e8d749c9904ea79822bfe59658bf6e,
title = "Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis",
abstract = "BACKGROUND/OBJECTIVE: Hyperuricemia has been proven to be an independent risk factor for chronic kidney disease (CKD). However, the role of hyperuricemia in the progression of CKD remains unclear. Thus, we performed a systematic review and meta-analysis to evaluate the efficacy and safety of febuxostat, a first line urate-lowering agent, in CKD patients with hyperuricemia. METHODS: We have systematically searched for randomized controlled trials assessing the efficacy and safety of febuxostat versus control in CKD patients with hyperuricemia through MEDLINE, PubMed, EMBASE, and Cochrane databases. All statistical analyses were conducted by using the statistical package Review Manager, version 5.3.5. Heterogeneity was assessed using the Cochrane Q and I tests and summary statistics were reported with 95{\%} confidence interval. Two-tailed test was used for analysis and a P value of <.05 is considered statistically significant. RESULTS: Eleven eligible trials with 1317 participants were included in the meta-analysis. A significant reduction in serum uric acid was found in the febuxostat treated group. Also, a significant higher eGFR was found in the febuxostat treated group among CKD stage 3 and 4 patients. No significant difference of major complication or death was identified between treatment and control groups. CONCLUSIONS: The meta-analysis showed that other than its urate-lowering effect, febuxostat presented a reno-protective effect in CKD patients. More studies with larger sample sizes and higher quality are required to clarify the role of febuxostat use in the progression of CKD.",
author = "Lin, {Tsu Chen} and Hung, {Lie Yee} and Chen, {Ying Chun} and Lo, {Wei Cheng} and Lin, {Chun Hung} and Tam, {Ka Wai} and Wu, {Mei Yi}",
year = "2019",
month = "7",
day = "1",
doi = "10.1097/MD.0000000000016311",
language = "English",
volume = "98",
pages = "e16311",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "29",

}

TY - JOUR

T1 - Effects of febuxostat on renal function in patients with chronic kidney disease

T2 - A systematic review and meta-analysis

AU - Lin, Tsu Chen

AU - Hung, Lie Yee

AU - Chen, Ying Chun

AU - Lo, Wei Cheng

AU - Lin, Chun Hung

AU - Tam, Ka Wai

AU - Wu, Mei Yi

PY - 2019/7/1

Y1 - 2019/7/1

N2 - BACKGROUND/OBJECTIVE: Hyperuricemia has been proven to be an independent risk factor for chronic kidney disease (CKD). However, the role of hyperuricemia in the progression of CKD remains unclear. Thus, we performed a systematic review and meta-analysis to evaluate the efficacy and safety of febuxostat, a first line urate-lowering agent, in CKD patients with hyperuricemia. METHODS: We have systematically searched for randomized controlled trials assessing the efficacy and safety of febuxostat versus control in CKD patients with hyperuricemia through MEDLINE, PubMed, EMBASE, and Cochrane databases. All statistical analyses were conducted by using the statistical package Review Manager, version 5.3.5. Heterogeneity was assessed using the Cochrane Q and I tests and summary statistics were reported with 95% confidence interval. Two-tailed test was used for analysis and a P value of <.05 is considered statistically significant. RESULTS: Eleven eligible trials with 1317 participants were included in the meta-analysis. A significant reduction in serum uric acid was found in the febuxostat treated group. Also, a significant higher eGFR was found in the febuxostat treated group among CKD stage 3 and 4 patients. No significant difference of major complication or death was identified between treatment and control groups. CONCLUSIONS: The meta-analysis showed that other than its urate-lowering effect, febuxostat presented a reno-protective effect in CKD patients. More studies with larger sample sizes and higher quality are required to clarify the role of febuxostat use in the progression of CKD.

AB - BACKGROUND/OBJECTIVE: Hyperuricemia has been proven to be an independent risk factor for chronic kidney disease (CKD). However, the role of hyperuricemia in the progression of CKD remains unclear. Thus, we performed a systematic review and meta-analysis to evaluate the efficacy and safety of febuxostat, a first line urate-lowering agent, in CKD patients with hyperuricemia. METHODS: We have systematically searched for randomized controlled trials assessing the efficacy and safety of febuxostat versus control in CKD patients with hyperuricemia through MEDLINE, PubMed, EMBASE, and Cochrane databases. All statistical analyses were conducted by using the statistical package Review Manager, version 5.3.5. Heterogeneity was assessed using the Cochrane Q and I tests and summary statistics were reported with 95% confidence interval. Two-tailed test was used for analysis and a P value of <.05 is considered statistically significant. RESULTS: Eleven eligible trials with 1317 participants were included in the meta-analysis. A significant reduction in serum uric acid was found in the febuxostat treated group. Also, a significant higher eGFR was found in the febuxostat treated group among CKD stage 3 and 4 patients. No significant difference of major complication or death was identified between treatment and control groups. CONCLUSIONS: The meta-analysis showed that other than its urate-lowering effect, febuxostat presented a reno-protective effect in CKD patients. More studies with larger sample sizes and higher quality are required to clarify the role of febuxostat use in the progression of CKD.

UR - http://www.scopus.com/inward/record.url?scp=85070469639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070469639&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000016311

DO - 10.1097/MD.0000000000016311

M3 - Article

C2 - 31335677

AN - SCOPUS:85070469639

VL - 98

SP - e16311

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 29

ER -